Autoimmune disorder treatment using RXR agonists
The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
1. A method of treating Parkinson's Disease, the method comprising elevating Treg cell numbers and suppressing Th17 cell numbers in an individual with Parkinson's Disease who does not have loss of appetite or weight loss, by administering a therapeutically effective amount of a retinoid X receptor (RXR) agonist having the structure of formula XII:
wherein R is H or lower alkyl of 1 to 6 carbons,
or a pharmaceutically acceptable salt thereof;
wherein the therapeutically effective amount is about 0.001 mg/kg/day to about 100 mg/kg/day;
whereby the balance between Treg and Th17 cell development is modulated to restrain autoimmunity.
2. The method according to claim 1 , wherein the RXR agonist is 3,7-dimethyl-6(S),7(S)-methano,7-[1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphth-7-yl]2(E),4(E) heptadienoic acid, and has the structure of formula XXIX:
3. The method according to claim 1 , wherein the therapeutically effective amount is about 0.001 mg/kg/day to about 0.2 mg/kg/day.
4. The method according to claim 1 , wherein the therapeutically effective amount is about 0.1 mg/kg/day to about 3.0 mg/kg/day.
5. The method according to claim 2 , wherein the RXR agonist is a salt of the compound of formula XXIX.
6. A method of treating an autoimmune aspect of Parkinson's Disease, the method comprising concurrently promoting differentiation of Treg cells and inhibiting differentiation of Th17 cells using a single agent by administering to an individual with Parkinson's Disease who does not have loss of appetite or weight loss a therapeutically effective amount of a retinoid X receptor (RXR) agonist having the structure of formula XII:
wherein R is H or lower alkyl of 1 to 6 carbons,
or a pharmaceutically acceptable salt thereof;
wherein the therapeutically effective amount is about 0.001 mg/kg/day to about 100 mg/kg/day;
wherein the autoimmune aspect is inflammation whereby the autoimmune aspect of Parkinson's disease is reduced.
7. The method according to claim 6 , wherein the RXR agonist is 3,7-dimethyl-6(S),7(S)-methano,7-[1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphth-7-yl]2(E),4(E) heptadienoic acid, and has the structure of formula XXIX:
8. The method according to claim 6 , wherein the therapeutically effective amount is about 0.001 mg/kg/day to about 0.2 mg/kg/day.
9. The method according to claim 6 , wherein the therapeutically effective amount is about 0.1 mg/kg/day to about 3.0 mg/kg/day.
10. The method according to claim 7 , wherein the RXR agonist is a salt of the compound of formula XXIX.
11. The method according to claim 1 , wherein the RXR agonist is administered by inhalation.
12. The method according to claim 6 , wherein the RXR agonist is administered by inhalation.
13. The method of claim according to claim 1 , wherein the therapeutically effective amount is about 0.01 mg/kg/day to about 0.1 mg/kg/day.
14. The method of claim according to claim 6 , wherein the therapeutically effective amount is about 0.01 mg/kg/day to about 0.1 mg/kg/day.